TY - CHAP M1 - Book, Section TI - Chronic Myeloid Leukemia A1 - Baljevic, Muhamed A1 - Jabbour, Elias A1 - Cortes, Jorge A1 - Kantarjian, Hagop M. A2 - Kantarjian, Hagop M. A2 - Wolff, Robert A. Y1 - 2016 N1 - T2 - The MD Anderson Manual of Medical Oncology, 3e AB - Chronic myeloid leukemia (CML) is a myeloproliferative disorder of pluripotent hematopoietic stem cells, characterized by the molecular BCR-ABL1 rearrangement, which drives a proliferative and survival advantage of the leukemic clone. About 30% to 50% of patients with CML are asymptomatic at diagnosis and are incidentally diagnosed during routine examination. Patients may also present with characteristic clinical findings secondary to large numbers of myeloid circulating progenitors, leading to splenomegaly, leukocytosis, or even isolated thrombocytosis. The landscape of CML has had a dramatic course, with a host of findings that have elucidated the biology and molecular pathology of the disease. The understanding of the molecular events led to the creation of the first targeted therapy—imatinib mesylate. Its impact on therapy and survival propelled CML as a model for modern molecular medicine in the fast-developing era of personalized targeted therapy. SN - PB - McGraw-Hill Medical CY - New York, NY Y2 - 2024/03/29 UR - hemonc.mhmedical.com/content.aspx?aid=1126740017 ER -